Skip to main content
Premium Trial:

Request an Annual Quote

Genometrix Signs High-Throughput Screening Deal with GeneMedicine

Premium

THE WOODLANDS, Texas--Genometrix, a maker of high-throughput microarray technology for applied genomics, diagnostic, and pharmaceutical development, announced it will sign an agreement with gene therapy products developer GeneMedicine to facilitate accelerated multiplex screening of biological responses in mouse tumor models. The collaboration will utilize Genometrix's medium-density DNA microarrays for high-throughput analysis of gene expression profiles in mice. Genometrix's Chief Scientific Officer Michael Hogan said Genometrix has developed proprietary technology for high-throughput, low-cost analysis of gene expression profiles. "During the past 24 months, special emphasis has been placed on the development of that technology for pharmaceutical development," Hogan said. "The new collaboration with GeneMedicine is timely because it allows Genometrix the opportunity to enter an important segment of the pharmaceutical development arena."

Filed under

The Scan

For Better Odds

Bloomberg reports that a child has been born following polygenic risk score screening as an embryo.

Booster Decision Expected

The New York Times reports the US Food and Drug Administration is expected to authorize a booster dose of the Pfizer-BioNTech SARS-CoV-2 vaccine this week for individuals over 65 or at high risk.

Snipping HIV Out

The Philadelphia Inquirer reports Temple University researchers are to test a gene-editing approach for treating HIV.

PLOS Papers on Cancer Risk Scores, Typhoid Fever in Colombia, Streptococcus Protection

In PLOS this week: application of cancer polygenic risk scores across ancestries, genetic diversity of typhoid fever-causing Salmonella, and more.